HINDVyome Holdings, Inc.
The schedule
- Sun20Sep
Management update on core clinical assets, trial timelines, and potential licensing or partnering signals.
- Thu22Oct
Risk of an equity offering to secure a 12-month forward cash runway ahead of the upcoming fiscal year-end audit.
- Fri12Feb
Q3 update to confirm whether the balance sheet is capable of funding operations through the 2027 calendar year.
- Thu25Feb
Exploration of strategic alternatives, including asset sales, reverse mergers, or a full buyout, given the compressed enterprise value.
- Tue11May
- Sun16May
Past
- Thu13Aug
Quarterly financial print with focus on operating cash burn, remaining runway, and potential going-concern language.
- Tue12May
Actual outcome: Bull · $2.11 at outcome
Stock rose 6.6% from event to outcome date, aligning with the bull trajectory.
Q1 2026 earnings around 2026-05-10 should clarify how quickly Vyome Holdings is burning cash after the 2025 restructuring and whether management still sees at least a year of runway at the current $2.32 share price. With revenue nearly immaterial and operating cash flow at -$5.76m, investors will focus on R&D spend, any update on business strategy, and language around going-concern risk. A relatively stable burn rate and disciplined costs could support a recovery toward $2.90, while a larger-than-expected loss or more cautious commentary on funding needs could push the stock down toward $2.90 as markets price in a higher probability of near-term dilution.